Long-Term Outcome of Postoperative Irradiation in Patients with Newly Diagnosed WHO Grade III Anaplastic Gliomas

Burger P.C. , Vogel F.S. , Green S.B. , Strike T.A. : Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer, 56: 1106–1111, 1985.

Kleihues P. , Soylemezoglu F. , Schauble B. , Scheithauer B.W. , Burger P.C. : Histopathology, classification, and grading of gliomas. Glia, 15: 211–221, 1995.

Kleihues P. , Burger P.C. , Scheithauer B.W. : The new WHO classification of brain tumours. Brain Pathol, 3: 255–268, 1993.

Kleihues P. , Sobin L.H. : World Health Organization classification of tumors. Cancer, 88: 2887, 2000.

See S.J. , Gilbert M.R. : Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol, 31: 618–634, 2004.

Walker M.D. , Strike T.A. , Sheline G.E. : An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol.

Walker M.D. , Green S.B. , Byar D.P. , Alexander E. Jr. , Batzdorf U. , Brooks W.H. , Hunt W.E. , MacCarty C.S. , Mahaley M.S. Jr. , Mealey J. Jr. , Owens G. , Ransohoff J. , Robertson J.T. , Shapiro W.R. , Smith K.R. Jr. , Wilson C.B. , Strike T.A. : Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med, 303: 1323–1329, 1980.

Walker M.D. , Alexander E. Jr. , Hunt W.E. , MacCarty C.S. , Mahaley M.S. Jr. , Mealey J. Jr. , Norrell H.A. , Owens G. , Ransohoff J. , Wilson C.B. , Gehan E.A. , Strike T.A. : Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 49: 333–343, 1978.

Kristiansen K. , Hagen S. , Kollevold T. , Torvik A. , Holme I. , Nesbakken R. , Hatlevoll R. , Lindgren M. , Brun A. , Lindgren S. , Notter G. , Andersen A.P. , Elgen K. : Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer, 47: 649–652, 1981.

Bauman G.S. , Ino Y. , Ueki K. , Zlatescu M.C. , Fisher B.J. , Macdonald D.R. , Stitt L. , Louis D.N. , Cairncross J.G. : Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys, 48: 825–830, 2000.

Cairncross J.G. , Ueki K. , Zlatescu M.C. , Lisle D.K. , Finkelstein D.M. , Hammond R.R. , Silver J.S. , Stark P.C. , Macdonald D.R. , Ino Y. , Ramsay D.A. , Louis D.N. : Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst, 90: 1473–1479, 1998.

Curran W.J. Jr. , Scott C.B. , Horton J. , Nelson J.S. , Weinstein A.S. , Nelson D.F. , Fischbach A.J. , Chang C.H. , Rotman M. , Asbell S.O. : Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol, 12: 219–227, 1992.

Nitta T. , Sato K. : Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer, 75: 2727–2731, 1995.

Gaspar L.E. , Fisher B.J. , Macdonald D.R. , LeBer D.V. , Halperin E.C. , Schold S.C. Jr. , Cairncross J.G. : Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys, 24: 55–57, 1992.

Hochberg F.H. , Pruitt A. : Assumptions in the radiotherapy of glioblastoma. Neurology, 30: 907–911, 1980.

Liang B.C. , Thornton A.F. Jr. , Sandler H.M. , Greenberg H.S. : Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg, 75: 559–563, 1991.

Clark T.G. , Bradburn M.J. , Love S.B. , Altman D.G. : Survival analysis part I: basic concepts and first analyses. Br J Cancer, 89: 232–238, 2003.

Bradburn M.J. , Clark T.G. , Love S.B. , Altman D.G. : Survival analysis part III: multivariate data analysis – choosing a model and assessing its adequacy and fit. Br J Cancer, 89: 605–611, 2003.

Bradburn M.J. , Clark T.G. , Love S.B. , Altman D.G. : Survival analysis part II: multivariate data analysis – an introduction to concepts and methods. Br J Cancer, 89: 431–436, 2003.

Hess K.R. : Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol, 42: 227–231, 1999.

Vuorinen V. , Hinkka S. , Farkkila M. , Jaaskelainen J. : Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien), 145: 5–10, 2003.

Tortosa A. , Vinolas N. , Villa S. , Verger E. , Gil J.M. , Brell M. , Caral L. , Pujol T. , Acebes J.J. , Ribalta T. , Ferrer I. , Graus F. : Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer, 97: 1063–1071, 2003.

Cohen Z.R. , Shi W. , Weinberg J.S. : Surgical resection of anaplastic astrocytoma: prognostic factors and outcome (Abstract). Neurooncology, 4: 367, 2002.

Laws E.R. , Shaffrey M.E. , Morris A. : Surgical management of intracranial gliomas - Does radical resection imrove outcome? Acta Neurochir, 85 (suppl): 47–53, 2003.

Oppitz U. , Maessen D. , Zunterer H. , Richter S. , Flentje M. : 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol, 53: 53–57, 1999.

Lee S.W. , Fraass B.A. , Marsh L.H. , Herbort K. , Gebarski S.S. , Martel M.K. , Radany E.H. , Lichter A.S. , Sandler H.M. : Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys, 43: 79–88, 1999.

Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol, 19: 509–518, 2001.

CBTRUS: Statistical report: Primary brain tumors in the United States 1995–1999. Central Brain Tumor Registry of the United States, Chicago, IL, 2002.

Werner-Wasik M. , Scott C.B. , Nelson D.F. , Gaspar L.E. , Murray K.J. , Fischbach J.A. , Nelson J.S. , Weinstein A.S. , Curran W.J. Jr. : Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83–02. Cancer, 77: 1535–1543, 1996.

Prados M.D. , Wara W.M. , Sneed P.K. , McDermott M. , Chang S.M. , Rabbitt J. , Page M. , Malec M. , Davis R.L. , Gutin P.H. , Lamborn K. , Wilson C.B. , Phillips T.L. , Larson D.A. : Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 49: 71–77, 2001.

Levin V.A. , Maor M.H. , Thall P.F. , Yung W.K. , Bruner J. , Sawaya R. , Kyritsis A.P. , Leeds N. , Woo S. , Rodriguez L. : Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 33: 357–364, 1995.

Fernandez P.M. , Zamorano L. , Yakar D. , Gaspar L. , Warmelink C. : Permanent iodine-125 implants in the up-front treatment of malignant gliomas. Neurosurgery, 36: 467–473, 1995.

Laperriere N.J. , Leung P.M. , McKenzie S. , Milosevic M. , Wong S. , Glen J. , Pintilie M. , Bernstein M. : Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys, 41: 1005–1011, 1998.

Stea B. , Rossman K. , Kittelson J. , Shetter A. , Hamilton A. , Cassady J.R. : Interstitial irradiation versus interstitial thermoradiotherapy for supratentorial malignant gliomas: a comparative survival analysis. Int J Radiat Oncol Biol Phys, 30: 591–600, 1994.

Sneed P.K. , Lamborn K.R. , Larson D.A. , Prados M.D. , Malec M.K. , McDermott M.W. , Weaver K.A. , Phillips T.L. , Wara W.M. , Gutin P.H. : Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 35: 37–44, 1996.

Sneed P.K. , Stauffer P.R. , McDermott M.W. , Diederich C.J. , Lamborn K.R. , Prados M.D. , Chang S. , Weaver K.A. , Spry L. , Malec M.K. , Lamb S.A. , Voss B. , Davis R.L. , Wara W.M. , Larson D.A. , Phillips T.L. , Gutin P.H. : Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/– hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 40: 287–295, 1998.

Lutterbach J. , Weigel P. , Guttenberger R. , Hinkelbein W. : Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme. Radiother Oncol, 53: 49–52, 1999.

Genc M. , Zorlu A.F. , Atahan I.L. : Accelerated hyperfractionated radiotherapy in supratentorial malignant astrocytomas. Radiother Oncol, 56: 233–238, 2000.

Nelson D.F. , Diener-West M. , Horton J. , Chang C.H. , Schoenfeld D. , Nelson J.S. : Combined modality approach to treatment of malignant gliomas—re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr, 279–284, 1988.

Brada M. , Sharpe G. , Rajan B. , Britton J. , Wilkins P.R. , Guerrero D. , Hines F. , Traish D. , Ashley S. : Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Radiat Oncol Biol Phys, 43: 287–292, 1999.

Jeremic B. , Shibamoto Y. , Grujicic D. , Stojanovic M. , Milicic B. , Nikolic N. , Dagovic A. , Aleksandrovic J. : Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study. J Neurooncol, 51: 133–141, 2001.

Goffman T.E. , Dachowski L.J. , Bobo H. , Oldfield E.H. , Steinberg S.M. , Cook J. , Mitchell J.B. , Katz D. , Smith R. , Glatstein E. : Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol, 10: 264–268, 1992.

Nelson D.F. , Diener-West M. , Weinstein A.S. , Schoenfeld D. , Nelson J.S. , Sause W.T. , Chang C.H. , Goodman R. , Carabell S. : A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys, 12: 1793–1800, 1986.

Prados M.D. , Scott C. , Sandler H. , Buckner J.C. , Phillips T. , Schultz C. , Urtasun R. , Davis R. , Gutin P. , Cascino T.L. , Greenberg H.S. , Curran W.J. Jr. : A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys, 45: 1109–1115, 1999.

Peterson K. , Harsh G. , Fisher P.G. , Adler J. , Le Q. : Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma. J Neurooncol, 53: 27–32, 2001.

Rao R.D. , Krishnan S. , Fitch T.R. , Schomberg P.J. , Dinapoli R.P. , Nordstrom K. , Scheithauer B. , O'Fallon J.R. , Maurer M.J. , Buckner J.C. : Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98–72–51. Int J Radiat Oncol Biol Phys, 61: 380–386, 2005.

Dillman R.O. , Shea W.M. , Tai D.F. , Mahdavi K. , Barth N.M. , Kharkar B.R. , Poor M.M. , Church C.K. , DePriest C. : Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro Oncol, 3: 35–41, 2001.

Buckner J.C. , Schomberg P.J. , McGinnis W.L. , Cascino T.L. , Scheithauer B.W. , O'fallon J.R. , Morton R.F. , Kuross S.A. , Mailliard J.A. , Hatfield A.K. , Cole J.T. , Steen P.D. , Bernath A.M. : A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer, 92: 420–433, 2001.

Cairncross G. , MacDonald D. , Ludwin S. , Lee D. , Cascino T. , Buckner J. , Fulton D. , Dropcho E. , Stewart D. , Schold C. Jr. : Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 12: 2013–2021, 1994.

Dehghani F. , Schachenmayr W. , Laun A. , Korf H.W. : Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl), 95: 493–504, 1998.

Daumas-Duport C. , Tucker M.L. , Kolles H. , Cervera P. , Beuvon F. , Varlet P. , Udo N. , Koziak M. , Chodkiewicz J.P. : Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol, 34: 61–78, 1997.

Schiffer D. , Dutto A. , Cavalla P. , Bosone I. , Chio A. , Villani R. , Bellotti C. : Prognostic factors in oligodendroglioma. Can J Neurol Sci, 24: 313–319, 1997.

Cairncross J.G. , Macdonald D.R. : Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol, 23: 360–364, 1988.

Paleologos N.A. , Macdonald D.R. , Vick N.A. , Cairncross J.G. : Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology, 53: 1141–1143, 1999.

Cairncross G. , Seiferheld W. , Shaw E. : An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas. Initial report of RTOG 9402. J Clin Oncol, 22: 107s, 2004.

Cairncross G. , Seiferheld W. , Shaw E. : Intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma: Initial report of RTOG 94-02. Presented at the Society of Neuro-Oncology 9th Annual Scientific Meeting, Toronto, Canada. November 18–21, 2004.

van den Bent M.J. , Chinot O. , Boogerd W. , Bravo M.J. , Taphoorn M.J. , Kros J.M. , van der Rijt C.C. , Vecht C.J. , De Beule N. , Baron B. : Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol, 14: 599–602, 2003.

van den Bent M.J. , Delattre J.Y. , Brandes A.A. : First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Presented at the American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13–17, 2005.

van den Bent M.J. , Taphoorn M.J. , Brandes A.A. , Menten J. , Stupp R. , Frenay M. , Chinot O. , Kros J.M. , van der Rijt C.C. , Vecht C. , Allgeier A. , Gorlia T. : Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol, 21: 2525–2528, 2003.

van den Bent M.J. , Keime-Guibert F. , Brandes A.A. , Taphoorn M.J. , Kros J.M. , Eskens F.A. , Carpentier A.F. : Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology, 57: 340–342, 2001.

Lebrun C. , Fontaine D. , Ramaioli A. , Vandenbos F. , Chanalet S. , Lonjon M. , Michiels J.F. , Bourg V. , Paquis P. , Chatel M. , Frenay M. : Long-term outcome of oligodendrogliomas. Neurology, 62: 1783–1787, 2004.

Vogelbaum M. , Berkey B. , Peereboom D. , Giannini D. , Suh J. , Brown P. , Blumenthal D. , Biggs C. , Schultz C. , Mehta M. : Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas. J Clin Oncol, 23: 119s (abstr 1520), 2005.